Immunome annual total assets
2019
2020
2021
2022
2023
2024
2025
Immunome Total Assets Growth & History (IMNM)
Immunome's total assets was $683.2M for fiscal 2025.
View full Immunome company overviewImmunome annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $683.2M | $442.9M | +184.38% |
| 2024 | 2024-12-31 | $240.2M | $91.7M | +61.73% |
| 2023 | 2023-12-31 | $148.5M | $124.5M | +517.73% |
| 2022 | 2022-12-31 | $24.0M | −$33.9M | −58.49% |
| 2021 | 2021-12-31 | $57.9M | $13.4M | +30.10% |
| 2020 | 2020-12-31 | $44.5M | $39.5M | +779.94% |
| 2019 | 2019-12-31 | $5.1M | — | — |
Immunome quarterly total assets
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $565.4M | $269.1M | +90.82% |
| Q1 2026 | 2026-03-31 | $619.8M | $277.1M | +80.86% |
| Q4 2025 | 2025-12-31 | $683.2M | $442.9M | +184.38% |
| Q3 2025 | 2025-09-30 | $299.4M | $42.5M | +16.54% |
| Q2 2025 | 2025-06-30 | $296.3M | $75,000 | +0.03% |
| Q1 2025 | 2025-03-31 | $342.7M | $22.9M | +7.17% |
| Q4 2024 | 2024-12-31 | $240.2M | $91.7M | +61.73% |
| Q3 2024 | 2024-09-30 | $256.9M | $163.7M | +175.76% |
| Q2 2024 | 2024-06-30 | $296.2M | $254.8M | +614.89% |
| Q1 2024 | 2024-03-31 | $319.8M | $271.6M | +564.58% |
| Q4 2023 | 2023-12-31 | $148.5M | $124.5M | +517.73% |
| Q3 2023 | 2023-09-30 | $93.2M | $62.6M | +204.99% |
| Q2 2023 | 2023-06-30 | $41.4M | $2.4M | +6.19% |
| Q1 2023 | 2023-03-31 | $48.1M | $386,000 | +0.81% |
| Q4 2022 | 2022-12-31 | $24.0M | −$33.9M | −58.49% |
| Q3 2022 | 2022-09-30 | $30.5M | −$32.0M | −51.17% |
| Q2 2022 | 2022-06-30 | $39.0M | −$25.1M | −39.17% |
| Q1 2022 | 2022-03-31 | $47.7M | $5.1M | +12.06% |
| Q4 2021 | 2021-12-31 | $57.9M | $13.4M | +30.10% |
| Q3 2021 | 2021-09-30 | $62.6M | $50.6M | +422.06% |
| Q2 2021 | 2021-06-30 | $64.1M | — | — |
| Q1 2021 | 2021-03-31 | $42.6M | — | — |
| Q4 2020 | 2020-12-31 | $44.5M | $39.5M | +779.94% |
| Q3 2020 | 2020-09-30 | $12.0M | — | — |
| Q4 2019 | 2019-12-31 | $5.1M | — | — |
Immunome total assets trends
Over the last five fiscal years, Immunome's total assets increased from $44.5M to $683.2M, a change of $638.7M. The latest reported quarter, Q2 2026, shows $565.4M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗